Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
- Status
- RECRUITING
- Phase
- PHASE1
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
- Status
- RECRUITING
- Phase
- PHASE1
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
- Status
- RECRUITING
- Phase
- NA
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
- Status
- RECRUITING
- Phase
- PHASE3